Technology startups have access to tax incentives that most other businesses do not - an R&D credit that can offset payroll taxes before the company has any income, a $10 million ($15 million for stock acquired after July 4, 2025) capital gain exclusion for qualified small business stock, and stock option structures that allow founders and employees to receive equity with minimal current tax cost. And the OBBBA added a major benefit: new §174A restores the immediate deduction for domestic research and development costs paid or incurred in tax years beginning after December 31, 2024, reversing the 5-year capitalization that applied for 2022 through 2024 and restoring the immediate deduction that made early-stage R&D spending tax-efficient.
Pre-OBBBA (tax years beginning after December 31, 2021, through 2024): Research and experimental (R&E) expenditures under §174 had to be capitalized and amortized over 5 years (15 years for foreign R&E), beginning at the midpoint of the year. A startup spending $500,000 on engineering salaries deducted only $50,000 in year one.
Post-OBBBA (P.L. 119-21): New §174A allows domestic R&E expenditures paid or incurred in tax years beginning after December 31, 2024 to be deducted in the year incurred (a taxpayer may instead elect to capitalize and amortize them ratably over at least 60 months); foreign R&E remains subject to 15-year amortization under §174. The $500,000 in engineering costs is deductible in year one. This materially reduces taxable income for R&D-intensive companies in early years.
The R&D credit is separate and unaffected: The §41 R&D credit calculation is based on qualified research expenses and is not changed by §174A. Both provisions apply simultaneously.
The research and development tax credit under IRC §41 equals 20% of qualified research expenses (QREs) above a base amount, or 14% under the alternative simplified credit (ASC) method. For startups, the ASC method is simpler - it equals 14% of QREs above 50% of average QREs for the prior three years. In the first years with no prior QRE history, the ASC rate is 6% of current year QREs.
What qualifies as QREs: wages paid to employees performing qualified research, contract research expenses (65% of amounts paid), and supply costs consumed in research. Software development costs incurred to develop software for sale qualify if the development involves technological uncertainty and experimentation; software developed primarily for internal use must also pass the additional high threshold of innovation test (Treas. Reg. §1.41-4(c)(6)).
Section 1202 excludes gain on the sale of qualified small business stock (QSBS) up to the greater of a per-issuer dollar cap or 10x the taxpayer's adjusted basis. For stock acquired after July 4, 2025, the exclusion is 50% of gain after 3 years, 75% after 4 years, and 100% after 5 or more years, and the dollar cap is $15 million (indexed after 2026); for stock acquired on or before July 4, 2025, 100% of gain is excluded only if the stock is held more than 5 years and the cap is $10 million. For a founder who invested $100,000 at formation in stock acquired after July 4, 2025 and holds it 5+ years, up to $15 million of gain on a startup exit is completely excluded from federal income tax. The requirements: the corporation must be a domestic C-corporation, aggregate gross assets must not have exceeded $75 million ($50 million for stock acquired on or before July 4, 2025) at any time before or immediately after issuance, and the corporation must be an active business in a qualifying industry (technology, software, manufacturing qualify; professional services, finance, hospitality do not).
The 10x basis multiplier matters for later-round investors: a Series A investor who puts in $2 million excludes up to $20 million of gain. The dollar-cap floor ($15 million for stock acquired after July 4, 2025; $10 million for earlier stock) matters for founders with small initial investments. QSBS planning - ensuring the corporation stays under the $75 million asset threshold ($50 million for earlier stock) at issuance, documenting original issuance directly from the corporation, and tracking holding periods - should begin at formation, not at the Series A.
Incentive stock options (ISOs) and nonqualified stock options (NSOs) create different tax events. ISOs: no ordinary income on grant or exercise (though the spread at exercise is an AMT preference item); long-term capital gain on sale if the holding period is met (2 years from grant, 1 year from exercise). NSOs: ordinary income at exercise equal to the spread between fair market value and exercise price; long-term capital gain on post-exercise appreciation after a 1-year holding period.
ISOs are generally better for employees at companies expected to appreciate significantly - the deferral of ordinary income recognition and the capital gain treatment at sale saves substantial tax at exit. The AMT exposure at ISO exercise is the primary risk, particularly for large exercises at high valuations. NSOs are simpler and are the only option for consultants, directors, and advisors (non-employees cannot receive ISOs).
When a founder receives equity subject to vesting, the default tax rule is that income is recognized as each tranche vests - at the fair market value at vesting. For a fast-growing startup, that means ordinary income at the high valuation when shares vest, not at the low value when shares were granted. The §83(b) election, filed within 30 days of receiving the restricted stock, elects to recognize income at grant (usually minimal for founders receiving shares at near-zero value) and converts all future appreciation to capital gain. Missing the 30-day window is permanent - there is no late-filing relief for §83(b) elections.